Aria Pharmaceuticals Inc. has described C-C chemokine receptor type 2 (CCR2; MCP-1-R) modulators reported to be useful for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis.
Ranok Therapeutics (Hangzhou) Co. Ltd. has divulged proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety covalently coupled to a GTPase KRAS (G12D mutant) targeting moiety through a linker reported to be useful for the treatment of cancer.
Researchers at Jiangsu Chia Tai Tianqing Pharmaceutical Group Co. Ltd. and Medshine Discovery Inc. have identified azobenzene compounds acting as endothelin-1 receptor (EDNRA; ETA) antagonists reported to be useful for the treatment of IgA nephropathy.
Insilico Medicine IP Ltd. has synthesized 3C-like proteinase (3CLpro; Mpro; nsp5) (SARS-CoV-2; COVID-19 virus) inhibitors reported to be useful for the treatment of SARS-CoV-2 infection (COVID-19).
With the rise of antibiotic resistance, treatment options against Yersinia pestis bacteria that cause pneumonic plague could also become limited. Antibody treatment has been effective in animal models of plague, but no approved human vaccine exists against this fatal disease.
It has been previously demonstrated that IL-17A plays a proinflammatory role in autoimmune diseases, and it has also been reported that IL-17A may take part in the occurrence and development of neurodegenerative disorders. Due to its association with both immunomodulation and inflammation, in a recent study, researchers from Shanghai Jiao Tong University aimed to investigate the role of IL-17A in the pathological process of glaucoma neuropathy.
Mesenchymal glioblastoma, a phenotype associated with poor clinical outcomes, is characterized by the expression of CD44 and chitinase 3-like protein 1 (CHI3L1) in mesenchymal glioma stem cells (GSCs). CHI3L1 has been implicated in several oncogenic pathways driving mesenchymal differentiation. However, the role of CHI3L1 as a paracrine modulator of GSC states, as well as the transcriptional regulatory network induced by CHI3L1 in GSCs, remains unknown.
Researchers from the Chinese Academy of Medical Sciences and Peking Union Medical College presented the discovery and preclinical evaluation of farnesoid X receptor (FXR) antagonists.
RSS
